Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![Acute Chronic Lymphocytic Leukemia CLL-GettyImages-1341097962]( "Understanding CLL And SLL Treatment Evolution")
Understanding CLL And SLL Treatment Evolution10/10/2025Tevogen Bio's Dr. Neal Flomenberg and Dr. Dolores Grosso discuss the shift from chemotherapy to targeted therapies such as Jaypirca and highlight Tevogen’s antigen-specific T cell platform as a new frontier in cancer and infectious disease treatment.
-
![Human lung cancer under microscope-GettyImages-2207680068]( "Advancing Telomere Targeting Therapy For Non-Small Cell Lung Cancer")
Advancing Telomere Targeting Therapy For Non-Small Cell Lung Cancer10/3/2025MAIA Biotechnology's Dr. Vlad Vitoc shares insights into how the company is advancing a novel therapeutic strategy that could redefine the treatment landscape for hard-to-treat cancers.
-
![Elderly woman parkinson's disease-GettyImages-2202004725]( "BlueRock Advances Cell Therapy For Parkinson's Disease")
BlueRock Advances Cell Therapy For Parkinson's Disease9/30/2025BlueRock Therapeutics has advanced its allogeneic stem cell-derived therapy bemdaneprocel into the pivotal Phase III trial for Parkinson’s disease, aiming to restore regulated dopamine signaling, improve quality of life, and potentially transform the treatment paradigm.
-
![GettyImages-2213747300-cancer-prostate]( "Driving Prostate Cancer Innovation Through Immunotherapy With OS Therapies' Dr. Robert Petit")
Driving Prostate Cancer Innovation Through Immunotherapy With OS Therapies' Dr. Robert Petit9/26/2025OS Therapies' Dr. Robert Petit discusses the evolving role of immunotherapy in prostate cancer.
-
![Natural Killer Cells Attacking Cancer Cell GettyImages-1339282270]( "The Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation")
The Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation9/26/2025Our recent Cell & Gene Live, Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, featuring expert panelists NKILT Therapeutics' Raphaël Ognar and NKore BioTherapeutics' Tracy Ryan covered the state of NK cell science, persistence challenges, safety, scalability, and the unique engineering breakthroughs shaping the future of oncology care.
-
![FDA Approved stamp-GettyImages-2196512628]( "Precigen Secures FDA Approval For PAPZIMEOS And Redefines RRP Treatment")
Precigen Secures FDA Approval For PAPZIMEOS And Redefines RRP Treatment8/27/2025Precigen has received FDA approval for PAPZIMEOS, the first therapy for recurrent respiratory papillomatosis, marking a major advance in patient care.
-
![25_08_Cell&GeneThePodcast_1280x720_FF_Ep02]( "Navigating Regulatory Complexity In Cell And Gene Therapy")
Navigating Regulatory Complexity In Cell And Gene Therapy8/26/2025This is a recap of the first three episodes of FDA Fridays, a special four-week series from Cell & Gene: The Podcast. These conversations shed light on the current challenges, best practices, and forward-looking strategies shaping the CGT regulatory environment.
-
![Medical research-GettyImages-1287846309]( "Accelerating NAMs For A Human-Based Future In CGT Development")
Accelerating NAMs For A Human-Based Future In CGT Development8/1/2025The Complement-ARIE Consortium, led by FNIH’s Stacey Adam, Ph.D., is advancing the development, validation, and regulatory adoption of human-based new approach methodologies (NAMs) to transform preclinical testing and accelerate cell and gene therapy development.
-
![Natural killer cell attacking cancer cell-GettyImages-1389774283]( "Navigating The Complexities Of NK Cell Therapy Development")
Navigating The Complexities Of NK Cell Therapy Development7/30/2025Deloitte's Amit Agarwal and Ashraf Husain share expert insights on how NK cell therapy developers can overcome manufacturing, supply chain, and commercialization challenges to successfully scale these promising therapies.
-
![Extracellular vesicles EVs-GettyImages-2009511436]( "Redefining CGT With Exosomes And EVs")
Redefining CGT With Exosomes And EVs7/16/2025July’s Cell & Gene Live featured a comprehensive look at the scientific advances, clinical promise, manufacturing hurdles, and regulatory considerations shaping extracellular vesicle and exosome-based therapies.
